Stoke Therapeutics offers a high-risk, asymmetric bet that zorevunersen can become the first disease-modifying Dravet therapy, with Biogen-backed funding and pivotal Phase 3 catalysts setting up a decisive 2027 inflection.
Overview
Stoke Therapeutics is a late-stage clinical biotech attempting to become the **first company to commercialize a disease-modifying therapy for Dravet syndrome** through zorevunersen, its lead TANGO-based antisense oligonucleotide. The investment case rests on a differentiated mechanism that upregulates endogenous SCN1A expression rather than treating symptoms alone. Existing approved Dravet therapies such as Fintepla, Epidiolex, and Diacomit are anti-seizure medicines, yet up to 57% of patients remain poorly controlled and none address the broader cognitive, motor, and behavioral burden. By contrast, Stoke has reported 4-year longitudinal open-label extension data showing durable improvements in neurotypical development, cognition, behavior, and major motor seizure reduction. The company completed enrollment in the 162-patient pivotal Phase 3 EMPEROR study in June 2026, with a rolling NDA planned to begin in Q1 2027 and a target launch in early 2028 if successful. Financially, **the Biogen partnership transformed Stoke’s risk profile**, preserving North American rights while shifting ex-North America commercialization to Biogen and providing milestone and royalty support. With **$411.0 million of cash and marketable securities as of March 31, 2026**, management believes funding extends into 2028, bridging the company through Phase 3 readout, regulatory filing, and launch preparations.